Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

Exclusion Criteria

• •1. Patients requiring antiarrhythmic therapy (excluding β-blockers or digoxin), symptomatic coronary artery disease, recent myocardial infarction within the past 6 months, or congestive heart failure exceeding New York Heart Association(NYHA) class II;
• •2. Poorly controlled severe hypertension;
• •3. History of HIV infection or active chronic hepatitis B or C (high viral DNA load);
• •4. Active pulmonary tuberculosis (TB) or receiving anti-TB treatment, or having received anti-TB treatment within the past year;
• •5. Other active clinically severe infections ;
• •6. Evidence of distant metastases outside the pelvis preoperatively;
• •7. Cachexia, organ decompensation;
• •8. History of pelvic or abdominal radiotherapy;
• •9. Multifocal colorectal cancer;
• •10. Patients requiring management for epileptic seizures (e.g., with steroids or antiepileptic therapy);
• •11. History of other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix or basal cell carcinoma of the skin;
• •12. Substance abuse or medical, psychological, or social conditions that may interfere with patient participation in the study or assessment of study results;
• •13. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, hyperthyroidism, hypothyroidism; patients with vitiligo or childhood asthma that has completely resolved and does not require any intervention in adulthood may be included; patients with asthma requiring bronchodilators for medical intervention cannot be included);
• •14. Vaccination with any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, etc.) within 4 weeks before enrollment;
• •15. Complications requiring long-term use of immunosuppressive drugs or systemic or local administration of corticosteroids with immunosuppressive effects (dose \> 10mg/day of prednisone or equivalent corticosteroids);
• •16. Known or suspected allergy to the investigational drug or any medication administered related to this trial;
• •17. Any unstable condition or situation that may jeopardize patient safety and compliance;
• •18. Pregnancy or lactation in women of childbearing potential who have not taken adequate contraceptive measures;
• •19. Refusal to sign the informed consent form.